Dax Kurbegov, MD, Vice President & Physician-in-Chief of Clinical Programs at Sarah Cannon, shares his perspective as a principal investigator at several Sarah Cannon sites for the newly launched STRIVE Study.
The purpose of the STRIVE Study is to develop and evaluate a blood test for detecting breast and other cancers early. The test, which is being developed by GRAIL, will use advanced technology to detect small pieces of genetic material released into the blood by tumors.
I’m enthused that Sarah Cannon is in great company, working alongside a handful of other preeminent cancer care organizations to make the STRIVE Study a success. The STRIVE Study is designed to enroll 120,000 women. That will make this one of the largest studies of its kind conducted to date, and it’s rewarding to know that Sarah Cannon is a part of the community that’s shaping the future landscape of cancer detection.
There are currently a number of tumor types for which screening technology is available, such as mammography screenings for breast cancer, and the technology works very well to save many lives. The major thrust of the STRIVE Study is to ask the question “Can a blood test, when complementing existing technologies and the individual’s clinical history, actually help us to more reliably catch cancers at an early stage?” We are looking at a future where a blood test, in addition to the usual screening strategies, can help to detect cancer early, and the earlier that cancer can be found, the higher the chance of successful treatment.
To learn more about the STRIVE Study, visit Join STRIVE.